Show simple item record

dc.contributor.authorAkay, Melek
dc.contributor.authorFuningana, Gabriel
dc.contributor.authorPatel, Grisma
dc.contributor.authorMustapha, Rami
dc.contributor.authorGjafa, Ernese
dc.contributor.authorNg, Tony
dc.contributor.authorNg, Kenrick
dc.contributor.authorFlynn, Michael J
dc.date.accessioned2021-11-22T14:38:28Z
dc.date.available2021-11-22T14:38:28Z
dc.date.issued2021-12
dc.date.submitted2021-06-21
dc.identifier.issn2366-1070
dc.identifier.others40487-021-00167-z
dc.identifier.other167
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/330824
dc.description.abstractNiraparib is an oral, potent, highly selective poly-ADP ribose polymerase 1 (PARP1) and PARP2 inhibitor. In most developed countries, it is approved as a maintenance treatment for epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients with complete or partial response to platinum-based therapy. These approvals are based on results of randomised, double-blind, placebo-controlled trials, particularly the NOVA trial and more recently the PRIMA trial. In this comprehensive review, we delve into the scientific basis of PARP inhibition, discussing both preclinical and clinical data which have led to the current approval status of niraparib. We also discuss ongoing trials and biological rationale of combination treatments involving niraparib, with particular focus on antiangiogenic drugs, immune checkpoint inhibitors and cyclic GMP-AMP synthase stimulator of interferon genes (cGAS/STING) pathway. In addition, we reflect on potential strategies and challenges of utilising current biomarkers for treatment selection of patients to ensure maximal benefit.
dc.languageen
dc.publisherSpringer Science and Business Media LLC
dc.subjectReview
dc.subjectCombined therapy
dc.subjectNiraparib
dc.subjectOvarian Cancer
dc.subjectPARP inhibitors
dc.subjectPharmacokinetics
dc.titleAn In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions.
dc.typeArticle
dc.date.updated2021-11-22T14:38:27Z
prism.endingPage364
prism.issueIdentifier2
prism.publicationNameOncol Ther
prism.startingPage347
prism.volume9
dc.identifier.doi10.17863/CAM.78267
dcterms.dateAccepted2021-07-22
rioxxterms.versionofrecord10.1007/s40487-021-00167-z
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.contributor.orcidFuningana, Gabriel [0000-0002-1197-2652]
dc.contributor.orcidNg, Kenrick [0000-0001-9132-4075]
dc.identifier.eissn2366-1089
cam.issuedOnline2021-08-07


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record